Intense Monitoring Study on Tyvyt
NCT04237233 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300
Last updated 2022-09-16
Summary
The study is a multi-center, prospective, non-interventional and observational study, and will collect data on the safety and efficacy of Tyvyt® in the treatment of Chinese patients with relapsed or refractory classical Hodgkin's lymphoma.
Conditions
- Relapsed or Refractory Classical Hodgkin's Lymphoma
Sponsors & Collaborators
-
Innovent Biologics (Suzhou) Co. Ltd.
lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-04-02
- Primary Completion
- 2023-06-30
- Completion
- 2023-12-31
Countries
- China
Study Locations
More Related Trials
-
Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma
NCT04661943 ·Status: COMPLETED ·Phase: PHASE2
-
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
NCT07200375 ·Status: RECRUITING
-
A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04657302 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma
NCT05900765 ·Status: RECRUITING ·Phase: PHASE2
-
The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
NCT06656234 ·Status: NOT_YET_RECRUITING
-
Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)
NCT05039658 ·Status: UNKNOWN ·Phase: PHASE1
-
Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma
NCT07162012 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)
NCT04660799 ·Status: COMPLETED ·Phase: PHASE2
-
The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP
NCT00440583 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Low Tumor Burden Untreated or Indolent NHL
NCT00414089 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Combination Study of CAR-T Therapy in r/r B-NHL
NCT05871684 ·Status: UNKNOWN ·Phase: PHASE2
-
Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL
NCT06695013 ·Status: RECRUITING ·Phase: PHASE2
-
A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
NCT05040906 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas
NCT05113069 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1
-
A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab
NCT01461928 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma
NCT05390528 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL)
NCT06170216 ·Status: COMPLETED
-
Study of BEBT-908 in Subjects With Advanced Hematological Tumors
NCT06082596 ·Status: COMPLETED ·Phase: PHASE1
-
BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)
NCT03520920 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
NCT07189065 ·Status: RECRUITING ·Phase: PHASE2
-
Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab
NCT03200977 ·Status: COMPLETED
-
Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy
NCT02499224 ·Status: COMPLETED ·Phase: PHASE1
-
Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL
NCT06742502 ·Status: RECRUITING ·Phase: PHASE2
-
Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma
NCT05179213 ·Status: UNKNOWN ·Phase: PHASE2
-
Observational Controlled Clinical Trials, on Adult Patients With T-lymphoblastic Lymphoma Treated With Intensive Chemo/Radiotherapy or Intensive Chemotherapy Followed by Transplant. Evaluation of Clinical, Anatomy -Pathological Parameters
NCT00882011 ·Status: UNKNOWN